There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy. Tirofiban is a glycoprotein IIb/IIIa used throughout the world now more comm...

Full description

Bibliographic Details
Main Authors: Hari Movva, Rani Rabah, Wondwossen Tekle, Alexandros Georgiadis, Laurie Preston, Hari Kotta, Ameer E. Hassan
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Interdisciplinary Neurosurgery
Subjects:
Acute Ischemic Stroke Intervention
ICH
MRS
Mechanical thrombectomy
Recanalization
Online Access:http://www.sciencedirect.com/science/article/pii/S2214751920304886

Internet

http://www.sciencedirect.com/science/article/pii/S2214751920304886

Similar Items